Pharma & Healthcare
Endothelin Antagonists Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
- Oct 12, 24
- ID: 163522
- Pages: 123
- Figures: 242
- Views: 13
Endothelin are the type of therapeutics that inhibits the action of endothelin and is thus effective for treating pulmonary arterial hypertension. This receptor, which plays a major role in regulating vascular tone, is found between the lumen and underlying media of the pulmonary vasculature. For patients suffering from the pulmonary hypertension, the body secrete high amount of endothelin that causes the blood vessels to be constricted and increase in the BP in the pulmonary arteries.
The global market for Endothelin Antagonists Therapeutics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Endothelin Antagonists Therapeutics, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Endothelin Antagonists Therapeutics by region & country, by Type, and by Application.
The Endothelin Antagonists Therapeutics market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Endothelin Antagonists Therapeutics.
Market Segmentation
By Company
Gilead Sciences, Inc
Sun Pharmaceutical Industries Ltd
Lupin
Zydus Group
Endo International plc
Mylan NV
Teva Pharmaceutical Industries Ltd
Sigmapharm Laboratories , LLC
Alembic Pharmaceuticals Limited
Hikma Pharmaceuticals PLC
Amneal Pharmaceuticals LLC
AstraZeneca
Johnsons & Johnsons Private limited
GSK Plc
Segment by Type:
Oral
Parenteral
Segment by Application
Cardiovascular Diseases
Scleroderma
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Endothelin Antagonists Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Endothelin Antagonists Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Endothelin Antagonists Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Endothelin Antagonists Therapeutics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Endothelin Antagonists Therapeutics, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Endothelin Antagonists Therapeutics by region & country, by Type, and by Application.
The Endothelin Antagonists Therapeutics market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Endothelin Antagonists Therapeutics.
Market Segmentation
By Company
Gilead Sciences, Inc
Sun Pharmaceutical Industries Ltd
Lupin
Zydus Group
Endo International plc
Mylan NV
Teva Pharmaceutical Industries Ltd
Sigmapharm Laboratories , LLC
Alembic Pharmaceuticals Limited
Hikma Pharmaceuticals PLC
Amneal Pharmaceuticals LLC
AstraZeneca
Johnsons & Johnsons Private limited
GSK Plc
Segment by Type:
Oral
Parenteral
Segment by Application
Cardiovascular Diseases
Scleroderma
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Endothelin Antagonists Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Endothelin Antagonists Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Endothelin Antagonists Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
1 Market Overview
1.1 Endothelin Antagonists Therapeutics Product Introduction
1.2 Global Endothelin Antagonists Therapeutics Market Size Forecast
1.2.1 Global Endothelin Antagonists Therapeutics Sales Value (2019-2030)
1.2.2 Global Endothelin Antagonists Therapeutics Sales Volume (2019-2030)
1.2.3 Global Endothelin Antagonists Therapeutics Sales Price (2019-2030)
1.3 Endothelin Antagonists Therapeutics Market Trends & Drivers
1.3.1 Endothelin Antagonists Therapeutics Industry Trends
1.3.2 Endothelin Antagonists Therapeutics Market Drivers & Opportunity
1.3.3 Endothelin Antagonists Therapeutics Market Challenges
1.3.4 Endothelin Antagonists Therapeutics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Endothelin Antagonists Therapeutics Players Revenue Ranking (2023)
2.2 Global Endothelin Antagonists Therapeutics Revenue by Company (2019-2024)
2.3 Global Endothelin Antagonists Therapeutics Players Sales Volume Ranking (2023)
2.4 Global Endothelin Antagonists Therapeutics Sales Volume by Company Players (2019-2024)
2.5 Global Endothelin Antagonists Therapeutics Average Price by Company (2019-2024)
2.6 Key Manufacturers Endothelin Antagonists Therapeutics Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Endothelin Antagonists Therapeutics Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Endothelin Antagonists Therapeutics
2.9 Endothelin Antagonists Therapeutics Market Competitive Analysis
2.9.1 Endothelin Antagonists Therapeutics Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Endothelin Antagonists Therapeutics Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Endothelin Antagonists Therapeutics as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Oral
3.1.2 Parenteral
3.2 Global Endothelin Antagonists Therapeutics Sales Value by Type
3.2.1 Global Endothelin Antagonists Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Endothelin Antagonists Therapeutics Sales Value, by Type (2019-2030)
3.2.3 Global Endothelin Antagonists Therapeutics Sales Value, by Type (%) (2019-2030)
3.3 Global Endothelin Antagonists Therapeutics Sales Volume by Type
3.3.1 Global Endothelin Antagonists Therapeutics Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Endothelin Antagonists Therapeutics Sales Volume, by Type (2019-2030)
3.3.3 Global Endothelin Antagonists Therapeutics Sales Volume, by Type (%) (2019-2030)
3.4 Global Endothelin Antagonists Therapeutics Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Cardiovascular Diseases
4.1.2 Scleroderma
4.1.3 Other
4.2 Global Endothelin Antagonists Therapeutics Sales Value by Application
4.2.1 Global Endothelin Antagonists Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Endothelin Antagonists Therapeutics Sales Value, by Application (2019-2030)
4.2.3 Global Endothelin Antagonists Therapeutics Sales Value, by Application (%) (2019-2030)
4.3 Global Endothelin Antagonists Therapeutics Sales Volume by Application
4.3.1 Global Endothelin Antagonists Therapeutics Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Endothelin Antagonists Therapeutics Sales Volume, by Application (2019-2030)
4.3.3 Global Endothelin Antagonists Therapeutics Sales Volume, by Application (%) (2019-2030)
4.4 Global Endothelin Antagonists Therapeutics Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Endothelin Antagonists Therapeutics Sales Value by Region
5.1.1 Global Endothelin Antagonists Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Endothelin Antagonists Therapeutics Sales Value by Region (2019-2024)
5.1.3 Global Endothelin Antagonists Therapeutics Sales Value by Region (2025-2030)
5.1.4 Global Endothelin Antagonists Therapeutics Sales Value by Region (%), (2019-2030)
5.2 Global Endothelin Antagonists Therapeutics Sales Volume by Region
5.2.1 Global Endothelin Antagonists Therapeutics Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Endothelin Antagonists Therapeutics Sales Volume by Region (2019-2024)
5.2.3 Global Endothelin Antagonists Therapeutics Sales Volume by Region (2025-2030)
5.2.4 Global Endothelin Antagonists Therapeutics Sales Volume by Region (%), (2019-2030)
5.3 Global Endothelin Antagonists Therapeutics Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Endothelin Antagonists Therapeutics Sales Value, 2019-2030
5.4.2 North America Endothelin Antagonists Therapeutics Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Endothelin Antagonists Therapeutics Sales Value, 2019-2030
5.5.2 Europe Endothelin Antagonists Therapeutics Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Endothelin Antagonists Therapeutics Sales Value, 2019-2030
5.6.2 Asia Pacific Endothelin Antagonists Therapeutics Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Endothelin Antagonists Therapeutics Sales Value, 2019-2030
5.7.2 South America Endothelin Antagonists Therapeutics Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Endothelin Antagonists Therapeutics Sales Value, 2019-2030
5.8.2 Middle East & Africa Endothelin Antagonists Therapeutics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Endothelin Antagonists Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Endothelin Antagonists Therapeutics Sales Value
6.2.1 Key Countries/Regions Endothelin Antagonists Therapeutics Sales Value, 2019-2030
6.2.2 Key Countries/Regions Endothelin Antagonists Therapeutics Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Endothelin Antagonists Therapeutics Sales Value, 2019-2030
6.3.2 United States Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Endothelin Antagonists Therapeutics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Endothelin Antagonists Therapeutics Sales Value, 2019-2030
6.4.2 Europe Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Endothelin Antagonists Therapeutics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Endothelin Antagonists Therapeutics Sales Value, 2019-2030
6.5.2 China Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
6.5.3 China Endothelin Antagonists Therapeutics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Endothelin Antagonists Therapeutics Sales Value, 2019-2030
6.6.2 Japan Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Endothelin Antagonists Therapeutics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Endothelin Antagonists Therapeutics Sales Value, 2019-2030
6.7.2 South Korea Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Endothelin Antagonists Therapeutics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Endothelin Antagonists Therapeutics Sales Value, 2019-2030
6.8.2 Southeast Asia Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Endothelin Antagonists Therapeutics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Endothelin Antagonists Therapeutics Sales Value, 2019-2030
6.9.2 India Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
6.9.3 India Endothelin Antagonists Therapeutics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Gilead Sciences, Inc
7.1.1 Gilead Sciences, Inc Company Information
7.1.2 Gilead Sciences, Inc Introduction and Business Overview
7.1.3 Gilead Sciences, Inc Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Gilead Sciences, Inc Endothelin Antagonists Therapeutics Product Offerings
7.1.5 Gilead Sciences, Inc Recent Development
7.2 Sun Pharmaceutical Industries Ltd
7.2.1 Sun Pharmaceutical Industries Ltd Company Information
7.2.2 Sun Pharmaceutical Industries Ltd Introduction and Business Overview
7.2.3 Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product Offerings
7.2.5 Sun Pharmaceutical Industries Ltd Recent Development
7.3 Lupin
7.3.1 Lupin Company Information
7.3.2 Lupin Introduction and Business Overview
7.3.3 Lupin Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Lupin Endothelin Antagonists Therapeutics Product Offerings
7.3.5 Lupin Recent Development
7.4 Zydus Group
7.4.1 Zydus Group Company Information
7.4.2 Zydus Group Introduction and Business Overview
7.4.3 Zydus Group Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Zydus Group Endothelin Antagonists Therapeutics Product Offerings
7.4.5 Zydus Group Recent Development
7.5 Endo International plc
7.5.1 Endo International plc Company Information
7.5.2 Endo International plc Introduction and Business Overview
7.5.3 Endo International plc Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Endo International plc Endothelin Antagonists Therapeutics Product Offerings
7.5.5 Endo International plc Recent Development
7.6 Mylan NV
7.6.1 Mylan NV Company Information
7.6.2 Mylan NV Introduction and Business Overview
7.6.3 Mylan NV Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Mylan NV Endothelin Antagonists Therapeutics Product Offerings
7.6.5 Mylan NV Recent Development
7.7 Teva Pharmaceutical Industries Ltd
7.7.1 Teva Pharmaceutical Industries Ltd Company Information
7.7.2 Teva Pharmaceutical Industries Ltd Introduction and Business Overview
7.7.3 Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product Offerings
7.7.5 Teva Pharmaceutical Industries Ltd Recent Development
7.8 Sigmapharm Laboratories , LLC
7.8.1 Sigmapharm Laboratories , LLC Company Information
7.8.2 Sigmapharm Laboratories , LLC Introduction and Business Overview
7.8.3 Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Product Offerings
7.8.5 Sigmapharm Laboratories , LLC Recent Development
7.9 Alembic Pharmaceuticals Limited
7.9.1 Alembic Pharmaceuticals Limited Company Information
7.9.2 Alembic Pharmaceuticals Limited Introduction and Business Overview
7.9.3 Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Product Offerings
7.9.5 Alembic Pharmaceuticals Limited Recent Development
7.10 Hikma Pharmaceuticals PLC
7.10.1 Hikma Pharmaceuticals PLC Company Information
7.10.2 Hikma Pharmaceuticals PLC Introduction and Business Overview
7.10.3 Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Product Offerings
7.10.5 Hikma Pharmaceuticals PLC Recent Development
7.11 Amneal Pharmaceuticals LLC
7.11.1 Amneal Pharmaceuticals LLC Company Information
7.11.2 Amneal Pharmaceuticals LLC Introduction and Business Overview
7.11.3 Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Product Offerings
7.11.5 Amneal Pharmaceuticals LLC Recent Development
7.12 AstraZeneca
7.12.1 AstraZeneca Company Information
7.12.2 AstraZeneca Introduction and Business Overview
7.12.3 AstraZeneca Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.12.4 AstraZeneca Endothelin Antagonists Therapeutics Product Offerings
7.12.5 AstraZeneca Recent Development
7.13 Johnsons & Johnsons Private limited
7.13.1 Johnsons & Johnsons Private limited Company Information
7.13.2 Johnsons & Johnsons Private limited Introduction and Business Overview
7.13.3 Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Product Offerings
7.13.5 Johnsons & Johnsons Private limited Recent Development
7.14 GSK Plc
7.14.1 GSK Plc Company Information
7.14.2 GSK Plc Introduction and Business Overview
7.14.3 GSK Plc Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.14.4 GSK Plc Endothelin Antagonists Therapeutics Product Offerings
7.14.5 GSK Plc Recent Development
8 Industry Chain Analysis
8.1 Endothelin Antagonists Therapeutics Industrial Chain
8.2 Endothelin Antagonists Therapeutics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Endothelin Antagonists Therapeutics Sales Model
8.5.2 Sales Channel
8.5.3 Endothelin Antagonists Therapeutics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
1.1 Endothelin Antagonists Therapeutics Product Introduction
1.2 Global Endothelin Antagonists Therapeutics Market Size Forecast
1.2.1 Global Endothelin Antagonists Therapeutics Sales Value (2019-2030)
1.2.2 Global Endothelin Antagonists Therapeutics Sales Volume (2019-2030)
1.2.3 Global Endothelin Antagonists Therapeutics Sales Price (2019-2030)
1.3 Endothelin Antagonists Therapeutics Market Trends & Drivers
1.3.1 Endothelin Antagonists Therapeutics Industry Trends
1.3.2 Endothelin Antagonists Therapeutics Market Drivers & Opportunity
1.3.3 Endothelin Antagonists Therapeutics Market Challenges
1.3.4 Endothelin Antagonists Therapeutics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Endothelin Antagonists Therapeutics Players Revenue Ranking (2023)
2.2 Global Endothelin Antagonists Therapeutics Revenue by Company (2019-2024)
2.3 Global Endothelin Antagonists Therapeutics Players Sales Volume Ranking (2023)
2.4 Global Endothelin Antagonists Therapeutics Sales Volume by Company Players (2019-2024)
2.5 Global Endothelin Antagonists Therapeutics Average Price by Company (2019-2024)
2.6 Key Manufacturers Endothelin Antagonists Therapeutics Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Endothelin Antagonists Therapeutics Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Endothelin Antagonists Therapeutics
2.9 Endothelin Antagonists Therapeutics Market Competitive Analysis
2.9.1 Endothelin Antagonists Therapeutics Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Endothelin Antagonists Therapeutics Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Endothelin Antagonists Therapeutics as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Oral
3.1.2 Parenteral
3.2 Global Endothelin Antagonists Therapeutics Sales Value by Type
3.2.1 Global Endothelin Antagonists Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Endothelin Antagonists Therapeutics Sales Value, by Type (2019-2030)
3.2.3 Global Endothelin Antagonists Therapeutics Sales Value, by Type (%) (2019-2030)
3.3 Global Endothelin Antagonists Therapeutics Sales Volume by Type
3.3.1 Global Endothelin Antagonists Therapeutics Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Endothelin Antagonists Therapeutics Sales Volume, by Type (2019-2030)
3.3.3 Global Endothelin Antagonists Therapeutics Sales Volume, by Type (%) (2019-2030)
3.4 Global Endothelin Antagonists Therapeutics Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Cardiovascular Diseases
4.1.2 Scleroderma
4.1.3 Other
4.2 Global Endothelin Antagonists Therapeutics Sales Value by Application
4.2.1 Global Endothelin Antagonists Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Endothelin Antagonists Therapeutics Sales Value, by Application (2019-2030)
4.2.3 Global Endothelin Antagonists Therapeutics Sales Value, by Application (%) (2019-2030)
4.3 Global Endothelin Antagonists Therapeutics Sales Volume by Application
4.3.1 Global Endothelin Antagonists Therapeutics Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Endothelin Antagonists Therapeutics Sales Volume, by Application (2019-2030)
4.3.3 Global Endothelin Antagonists Therapeutics Sales Volume, by Application (%) (2019-2030)
4.4 Global Endothelin Antagonists Therapeutics Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Endothelin Antagonists Therapeutics Sales Value by Region
5.1.1 Global Endothelin Antagonists Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Endothelin Antagonists Therapeutics Sales Value by Region (2019-2024)
5.1.3 Global Endothelin Antagonists Therapeutics Sales Value by Region (2025-2030)
5.1.4 Global Endothelin Antagonists Therapeutics Sales Value by Region (%), (2019-2030)
5.2 Global Endothelin Antagonists Therapeutics Sales Volume by Region
5.2.1 Global Endothelin Antagonists Therapeutics Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Endothelin Antagonists Therapeutics Sales Volume by Region (2019-2024)
5.2.3 Global Endothelin Antagonists Therapeutics Sales Volume by Region (2025-2030)
5.2.4 Global Endothelin Antagonists Therapeutics Sales Volume by Region (%), (2019-2030)
5.3 Global Endothelin Antagonists Therapeutics Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Endothelin Antagonists Therapeutics Sales Value, 2019-2030
5.4.2 North America Endothelin Antagonists Therapeutics Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Endothelin Antagonists Therapeutics Sales Value, 2019-2030
5.5.2 Europe Endothelin Antagonists Therapeutics Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Endothelin Antagonists Therapeutics Sales Value, 2019-2030
5.6.2 Asia Pacific Endothelin Antagonists Therapeutics Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Endothelin Antagonists Therapeutics Sales Value, 2019-2030
5.7.2 South America Endothelin Antagonists Therapeutics Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Endothelin Antagonists Therapeutics Sales Value, 2019-2030
5.8.2 Middle East & Africa Endothelin Antagonists Therapeutics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Endothelin Antagonists Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Endothelin Antagonists Therapeutics Sales Value
6.2.1 Key Countries/Regions Endothelin Antagonists Therapeutics Sales Value, 2019-2030
6.2.2 Key Countries/Regions Endothelin Antagonists Therapeutics Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Endothelin Antagonists Therapeutics Sales Value, 2019-2030
6.3.2 United States Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Endothelin Antagonists Therapeutics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Endothelin Antagonists Therapeutics Sales Value, 2019-2030
6.4.2 Europe Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Endothelin Antagonists Therapeutics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Endothelin Antagonists Therapeutics Sales Value, 2019-2030
6.5.2 China Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
6.5.3 China Endothelin Antagonists Therapeutics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Endothelin Antagonists Therapeutics Sales Value, 2019-2030
6.6.2 Japan Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Endothelin Antagonists Therapeutics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Endothelin Antagonists Therapeutics Sales Value, 2019-2030
6.7.2 South Korea Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Endothelin Antagonists Therapeutics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Endothelin Antagonists Therapeutics Sales Value, 2019-2030
6.8.2 Southeast Asia Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Endothelin Antagonists Therapeutics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Endothelin Antagonists Therapeutics Sales Value, 2019-2030
6.9.2 India Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
6.9.3 India Endothelin Antagonists Therapeutics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Gilead Sciences, Inc
7.1.1 Gilead Sciences, Inc Company Information
7.1.2 Gilead Sciences, Inc Introduction and Business Overview
7.1.3 Gilead Sciences, Inc Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Gilead Sciences, Inc Endothelin Antagonists Therapeutics Product Offerings
7.1.5 Gilead Sciences, Inc Recent Development
7.2 Sun Pharmaceutical Industries Ltd
7.2.1 Sun Pharmaceutical Industries Ltd Company Information
7.2.2 Sun Pharmaceutical Industries Ltd Introduction and Business Overview
7.2.3 Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product Offerings
7.2.5 Sun Pharmaceutical Industries Ltd Recent Development
7.3 Lupin
7.3.1 Lupin Company Information
7.3.2 Lupin Introduction and Business Overview
7.3.3 Lupin Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Lupin Endothelin Antagonists Therapeutics Product Offerings
7.3.5 Lupin Recent Development
7.4 Zydus Group
7.4.1 Zydus Group Company Information
7.4.2 Zydus Group Introduction and Business Overview
7.4.3 Zydus Group Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Zydus Group Endothelin Antagonists Therapeutics Product Offerings
7.4.5 Zydus Group Recent Development
7.5 Endo International plc
7.5.1 Endo International plc Company Information
7.5.2 Endo International plc Introduction and Business Overview
7.5.3 Endo International plc Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Endo International plc Endothelin Antagonists Therapeutics Product Offerings
7.5.5 Endo International plc Recent Development
7.6 Mylan NV
7.6.1 Mylan NV Company Information
7.6.2 Mylan NV Introduction and Business Overview
7.6.3 Mylan NV Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Mylan NV Endothelin Antagonists Therapeutics Product Offerings
7.6.5 Mylan NV Recent Development
7.7 Teva Pharmaceutical Industries Ltd
7.7.1 Teva Pharmaceutical Industries Ltd Company Information
7.7.2 Teva Pharmaceutical Industries Ltd Introduction and Business Overview
7.7.3 Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product Offerings
7.7.5 Teva Pharmaceutical Industries Ltd Recent Development
7.8 Sigmapharm Laboratories , LLC
7.8.1 Sigmapharm Laboratories , LLC Company Information
7.8.2 Sigmapharm Laboratories , LLC Introduction and Business Overview
7.8.3 Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Product Offerings
7.8.5 Sigmapharm Laboratories , LLC Recent Development
7.9 Alembic Pharmaceuticals Limited
7.9.1 Alembic Pharmaceuticals Limited Company Information
7.9.2 Alembic Pharmaceuticals Limited Introduction and Business Overview
7.9.3 Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Product Offerings
7.9.5 Alembic Pharmaceuticals Limited Recent Development
7.10 Hikma Pharmaceuticals PLC
7.10.1 Hikma Pharmaceuticals PLC Company Information
7.10.2 Hikma Pharmaceuticals PLC Introduction and Business Overview
7.10.3 Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Product Offerings
7.10.5 Hikma Pharmaceuticals PLC Recent Development
7.11 Amneal Pharmaceuticals LLC
7.11.1 Amneal Pharmaceuticals LLC Company Information
7.11.2 Amneal Pharmaceuticals LLC Introduction and Business Overview
7.11.3 Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Product Offerings
7.11.5 Amneal Pharmaceuticals LLC Recent Development
7.12 AstraZeneca
7.12.1 AstraZeneca Company Information
7.12.2 AstraZeneca Introduction and Business Overview
7.12.3 AstraZeneca Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.12.4 AstraZeneca Endothelin Antagonists Therapeutics Product Offerings
7.12.5 AstraZeneca Recent Development
7.13 Johnsons & Johnsons Private limited
7.13.1 Johnsons & Johnsons Private limited Company Information
7.13.2 Johnsons & Johnsons Private limited Introduction and Business Overview
7.13.3 Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Product Offerings
7.13.5 Johnsons & Johnsons Private limited Recent Development
7.14 GSK Plc
7.14.1 GSK Plc Company Information
7.14.2 GSK Plc Introduction and Business Overview
7.14.3 GSK Plc Endothelin Antagonists Therapeutics Sales, Revenue and Gross Margin (2019-2024)
7.14.4 GSK Plc Endothelin Antagonists Therapeutics Product Offerings
7.14.5 GSK Plc Recent Development
8 Industry Chain Analysis
8.1 Endothelin Antagonists Therapeutics Industrial Chain
8.2 Endothelin Antagonists Therapeutics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Endothelin Antagonists Therapeutics Sales Model
8.5.2 Sales Channel
8.5.3 Endothelin Antagonists Therapeutics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Endothelin Antagonists Therapeutics Market Trends
Table 2. Endothelin Antagonists Therapeutics Market Drivers & Opportunity
Table 3. Endothelin Antagonists Therapeutics Market Challenges
Table 4. Endothelin Antagonists Therapeutics Market Restraints
Table 5. Global Endothelin Antagonists Therapeutics Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Endothelin Antagonists Therapeutics Revenue Market Share by Company (2019-2024)
Table 7. Global Endothelin Antagonists Therapeutics Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Endothelin Antagonists Therapeutics Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Endothelin Antagonists Therapeutics Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Endothelin Antagonists Therapeutics Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Endothelin Antagonists Therapeutics Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Endothelin Antagonists Therapeutics
Table 13. Global Endothelin Antagonists Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Endothelin Antagonists Therapeutics as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Endothelin Antagonists Therapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Endothelin Antagonists Therapeutics Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Endothelin Antagonists Therapeutics Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Endothelin Antagonists Therapeutics Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Endothelin Antagonists Therapeutics Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Endothelin Antagonists Therapeutics Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Endothelin Antagonists Therapeutics Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Endothelin Antagonists Therapeutics Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Endothelin Antagonists Therapeutics Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Endothelin Antagonists Therapeutics Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Endothelin Antagonists Therapeutics Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Endothelin Antagonists Therapeutics Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Endothelin Antagonists Therapeutics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Endothelin Antagonists Therapeutics Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Endothelin Antagonists Therapeutics Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Endothelin Antagonists Therapeutics Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Endothelin Antagonists Therapeutics Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Endothelin Antagonists Therapeutics Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Endothelin Antagonists Therapeutics Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Endothelin Antagonists Therapeutics Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Endothelin Antagonists Therapeutics Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Endothelin Antagonists Therapeutics Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Endothelin Antagonists Therapeutics Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Endothelin Antagonists Therapeutics Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Endothelin Antagonists Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Endothelin Antagonists Therapeutics Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Endothelin Antagonists Therapeutics Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Endothelin Antagonists Therapeutics Sales Value by Region (2019-2024) & (%)
Table 44. Global Endothelin Antagonists Therapeutics Sales Value by Region (2025-2030) & (%)
Table 45. Global Endothelin Antagonists Therapeutics Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Endothelin Antagonists Therapeutics Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Endothelin Antagonists Therapeutics Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Endothelin Antagonists Therapeutics Sales Volume by Region (2019-2024) & (%)
Table 49. Global Endothelin Antagonists Therapeutics Sales Volume by Region (2025-2030) & (%)
Table 50. Global Endothelin Antagonists Therapeutics Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Endothelin Antagonists Therapeutics Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Endothelin Antagonists Therapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Endothelin Antagonists Therapeutics Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Endothelin Antagonists Therapeutics Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Endothelin Antagonists Therapeutics Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Endothelin Antagonists Therapeutics Sales Volume, (2025-2030) & (K Units)
Table 57. Gilead Sciences, Inc Company Information
Table 58. Gilead Sciences, Inc Introduction and Business Overview
Table 59. Gilead Sciences, Inc Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. Gilead Sciences, Inc Endothelin Antagonists Therapeutics Product Offerings
Table 61. Gilead Sciences, Inc Recent Development
Table 62. Sun Pharmaceutical Industries Ltd Company Information
Table 63. Sun Pharmaceutical Industries Ltd Introduction and Business Overview
Table 64. Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product Offerings
Table 66. Sun Pharmaceutical Industries Ltd Recent Development
Table 67. Lupin Company Information
Table 68. Lupin Introduction and Business Overview
Table 69. Lupin Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. Lupin Endothelin Antagonists Therapeutics Product Offerings
Table 71. Lupin Recent Development
Table 72. Zydus Group Company Information
Table 73. Zydus Group Introduction and Business Overview
Table 74. Zydus Group Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Zydus Group Endothelin Antagonists Therapeutics Product Offerings
Table 76. Zydus Group Recent Development
Table 77. Endo International plc Company Information
Table 78. Endo International plc Introduction and Business Overview
Table 79. Endo International plc Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Endo International plc Endothelin Antagonists Therapeutics Product Offerings
Table 81. Endo International plc Recent Development
Table 82. Mylan NV Company Information
Table 83. Mylan NV Introduction and Business Overview
Table 84. Mylan NV Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Mylan NV Endothelin Antagonists Therapeutics Product Offerings
Table 86. Mylan NV Recent Development
Table 87. Teva Pharmaceutical Industries Ltd Company Information
Table 88. Teva Pharmaceutical Industries Ltd Introduction and Business Overview
Table 89. Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product Offerings
Table 91. Teva Pharmaceutical Industries Ltd Recent Development
Table 92. Sigmapharm Laboratories , LLC Company Information
Table 93. Sigmapharm Laboratories , LLC Introduction and Business Overview
Table 94. Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Product Offerings
Table 96. Sigmapharm Laboratories , LLC Recent Development
Table 97. Alembic Pharmaceuticals Limited Company Information
Table 98. Alembic Pharmaceuticals Limited Introduction and Business Overview
Table 99. Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Product Offerings
Table 101. Alembic Pharmaceuticals Limited Recent Development
Table 102. Hikma Pharmaceuticals PLC Company Information
Table 103. Hikma Pharmaceuticals PLC Introduction and Business Overview
Table 104. Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Product Offerings
Table 106. Hikma Pharmaceuticals PLC Recent Development
Table 107. Amneal Pharmaceuticals LLC Company Information
Table 108. Amneal Pharmaceuticals LLC Introduction and Business Overview
Table 109. Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Product Offerings
Table 111. Amneal Pharmaceuticals LLC Recent Development
Table 112. AstraZeneca Company Information
Table 113. AstraZeneca Introduction and Business Overview
Table 114. AstraZeneca Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115. AstraZeneca Endothelin Antagonists Therapeutics Product Offerings
Table 116. AstraZeneca Recent Development
Table 117. Johnsons & Johnsons Private limited Company Information
Table 118. Johnsons & Johnsons Private limited Introduction and Business Overview
Table 119. Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 120. Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Product Offerings
Table 121. Johnsons & Johnsons Private limited Recent Development
Table 122. GSK Plc Company Information
Table 123. GSK Plc Introduction and Business Overview
Table 124. GSK Plc Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 125. GSK Plc Endothelin Antagonists Therapeutics Product Offerings
Table 126. GSK Plc Recent Development
Table 127. Key Raw Materials Lists
Table 128. Raw Materials Key Suppliers Lists
Table 129. Endothelin Antagonists Therapeutics Downstream Customers
Table 130. Endothelin Antagonists Therapeutics Distributors List
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Endothelin Antagonists Therapeutics Product Picture
Figure 2. Global Endothelin Antagonists Therapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Endothelin Antagonists Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Endothelin Antagonists Therapeutics Sales Volume (2019-2030) & (K Units)
Figure 5. Global Endothelin Antagonists Therapeutics Sales Price (2019-2030) & (US$/Unit)
Figure 6. Endothelin Antagonists Therapeutics Report Years Considered
Figure 7. Global Endothelin Antagonists Therapeutics Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Endothelin Antagonists Therapeutics Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Endothelin Antagonists Therapeutics Revenue in 2023
Figure 10. Endothelin Antagonists Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Oral Picture
Figure 12. Parenteral Picture
Figure 13. Global Endothelin Antagonists Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Endothelin Antagonists Therapeutics Sales Value Market Share by Type, 2023 & 2030
Figure 15. Global Endothelin Antagonists Therapeutics Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 16. Global Endothelin Antagonists Therapeutics Sales Volume Market Share by Type, 2023 & 2030
Figure 17. Global Endothelin Antagonists Therapeutics Price by Type (2019-2030) & (US$/Unit)
Figure 18. Product Picture of Cardiovascular Diseases
Figure 19. Product Picture of Scleroderma
Figure 20. Product Picture of Other
Figure 21. Global Endothelin Antagonists Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global Endothelin Antagonists Therapeutics Sales Value Market Share by Application, 2023 & 2030
Figure 23. Global Endothelin Antagonists Therapeutics Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 24. Global Endothelin Antagonists Therapeutics Sales Volume Market Share by Application, 2023 & 2030
Figure 25. Global Endothelin Antagonists Therapeutics Price by Application (2019-2030) & (US$/Unit)
Figure 26. North America Endothelin Antagonists Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 27. North America Endothelin Antagonists Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 28. Europe Endothelin Antagonists Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 29. Europe Endothelin Antagonists Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 30. Asia Pacific Endothelin Antagonists Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Endothelin Antagonists Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 32. South America Endothelin Antagonists Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 33. South America Endothelin Antagonists Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 34. Middle East & Africa Endothelin Antagonists Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 35. Middle East & Africa Endothelin Antagonists Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 36. Key Countries/Regions Endothelin Antagonists Therapeutics Sales Value (%), (2019-2030)
Figure 37. Key Countries/Regions Endothelin Antagonists Therapeutics Sales Volume (%), (2019-2030)
Figure 38. United States Endothelin Antagonists Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 39. United States Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 40. United States Endothelin Antagonists Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 41. Europe Endothelin Antagonists Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 42. Europe Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 43. Europe Endothelin Antagonists Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 44. China Endothelin Antagonists Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 45. China Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 46. China Endothelin Antagonists Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 47. Japan Endothelin Antagonists Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 48. Japan Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 49. Japan Endothelin Antagonists Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 50. South Korea Endothelin Antagonists Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 51. South Korea Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 52. South Korea Endothelin Antagonists Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 53. Southeast Asia Endothelin Antagonists Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 54. Southeast Asia Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 55. Southeast Asia Endothelin Antagonists Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 56. India Endothelin Antagonists Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 57. India Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 58. India Endothelin Antagonists Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 59. Endothelin Antagonists Therapeutics Industrial Chain
Figure 60. Endothelin Antagonists Therapeutics Manufacturing Cost Structure
Figure 61. Channels of Distribution (Direct Sales, and Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Table 1. Endothelin Antagonists Therapeutics Market Trends
Table 2. Endothelin Antagonists Therapeutics Market Drivers & Opportunity
Table 3. Endothelin Antagonists Therapeutics Market Challenges
Table 4. Endothelin Antagonists Therapeutics Market Restraints
Table 5. Global Endothelin Antagonists Therapeutics Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Endothelin Antagonists Therapeutics Revenue Market Share by Company (2019-2024)
Table 7. Global Endothelin Antagonists Therapeutics Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Endothelin Antagonists Therapeutics Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Endothelin Antagonists Therapeutics Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Endothelin Antagonists Therapeutics Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Endothelin Antagonists Therapeutics Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Endothelin Antagonists Therapeutics
Table 13. Global Endothelin Antagonists Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Endothelin Antagonists Therapeutics as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Endothelin Antagonists Therapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Endothelin Antagonists Therapeutics Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Endothelin Antagonists Therapeutics Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Endothelin Antagonists Therapeutics Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Endothelin Antagonists Therapeutics Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Endothelin Antagonists Therapeutics Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Endothelin Antagonists Therapeutics Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Endothelin Antagonists Therapeutics Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Endothelin Antagonists Therapeutics Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Endothelin Antagonists Therapeutics Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Endothelin Antagonists Therapeutics Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Endothelin Antagonists Therapeutics Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Endothelin Antagonists Therapeutics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Endothelin Antagonists Therapeutics Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Endothelin Antagonists Therapeutics Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Endothelin Antagonists Therapeutics Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Endothelin Antagonists Therapeutics Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Endothelin Antagonists Therapeutics Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Endothelin Antagonists Therapeutics Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Endothelin Antagonists Therapeutics Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Endothelin Antagonists Therapeutics Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Endothelin Antagonists Therapeutics Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Endothelin Antagonists Therapeutics Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Endothelin Antagonists Therapeutics Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Endothelin Antagonists Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Endothelin Antagonists Therapeutics Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Endothelin Antagonists Therapeutics Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Endothelin Antagonists Therapeutics Sales Value by Region (2019-2024) & (%)
Table 44. Global Endothelin Antagonists Therapeutics Sales Value by Region (2025-2030) & (%)
Table 45. Global Endothelin Antagonists Therapeutics Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Endothelin Antagonists Therapeutics Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Endothelin Antagonists Therapeutics Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Endothelin Antagonists Therapeutics Sales Volume by Region (2019-2024) & (%)
Table 49. Global Endothelin Antagonists Therapeutics Sales Volume by Region (2025-2030) & (%)
Table 50. Global Endothelin Antagonists Therapeutics Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Endothelin Antagonists Therapeutics Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Endothelin Antagonists Therapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Endothelin Antagonists Therapeutics Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Endothelin Antagonists Therapeutics Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Endothelin Antagonists Therapeutics Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Endothelin Antagonists Therapeutics Sales Volume, (2025-2030) & (K Units)
Table 57. Gilead Sciences, Inc Company Information
Table 58. Gilead Sciences, Inc Introduction and Business Overview
Table 59. Gilead Sciences, Inc Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. Gilead Sciences, Inc Endothelin Antagonists Therapeutics Product Offerings
Table 61. Gilead Sciences, Inc Recent Development
Table 62. Sun Pharmaceutical Industries Ltd Company Information
Table 63. Sun Pharmaceutical Industries Ltd Introduction and Business Overview
Table 64. Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product Offerings
Table 66. Sun Pharmaceutical Industries Ltd Recent Development
Table 67. Lupin Company Information
Table 68. Lupin Introduction and Business Overview
Table 69. Lupin Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. Lupin Endothelin Antagonists Therapeutics Product Offerings
Table 71. Lupin Recent Development
Table 72. Zydus Group Company Information
Table 73. Zydus Group Introduction and Business Overview
Table 74. Zydus Group Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Zydus Group Endothelin Antagonists Therapeutics Product Offerings
Table 76. Zydus Group Recent Development
Table 77. Endo International plc Company Information
Table 78. Endo International plc Introduction and Business Overview
Table 79. Endo International plc Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Endo International plc Endothelin Antagonists Therapeutics Product Offerings
Table 81. Endo International plc Recent Development
Table 82. Mylan NV Company Information
Table 83. Mylan NV Introduction and Business Overview
Table 84. Mylan NV Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Mylan NV Endothelin Antagonists Therapeutics Product Offerings
Table 86. Mylan NV Recent Development
Table 87. Teva Pharmaceutical Industries Ltd Company Information
Table 88. Teva Pharmaceutical Industries Ltd Introduction and Business Overview
Table 89. Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product Offerings
Table 91. Teva Pharmaceutical Industries Ltd Recent Development
Table 92. Sigmapharm Laboratories , LLC Company Information
Table 93. Sigmapharm Laboratories , LLC Introduction and Business Overview
Table 94. Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Product Offerings
Table 96. Sigmapharm Laboratories , LLC Recent Development
Table 97. Alembic Pharmaceuticals Limited Company Information
Table 98. Alembic Pharmaceuticals Limited Introduction and Business Overview
Table 99. Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Product Offerings
Table 101. Alembic Pharmaceuticals Limited Recent Development
Table 102. Hikma Pharmaceuticals PLC Company Information
Table 103. Hikma Pharmaceuticals PLC Introduction and Business Overview
Table 104. Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Product Offerings
Table 106. Hikma Pharmaceuticals PLC Recent Development
Table 107. Amneal Pharmaceuticals LLC Company Information
Table 108. Amneal Pharmaceuticals LLC Introduction and Business Overview
Table 109. Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Product Offerings
Table 111. Amneal Pharmaceuticals LLC Recent Development
Table 112. AstraZeneca Company Information
Table 113. AstraZeneca Introduction and Business Overview
Table 114. AstraZeneca Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115. AstraZeneca Endothelin Antagonists Therapeutics Product Offerings
Table 116. AstraZeneca Recent Development
Table 117. Johnsons & Johnsons Private limited Company Information
Table 118. Johnsons & Johnsons Private limited Introduction and Business Overview
Table 119. Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 120. Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Product Offerings
Table 121. Johnsons & Johnsons Private limited Recent Development
Table 122. GSK Plc Company Information
Table 123. GSK Plc Introduction and Business Overview
Table 124. GSK Plc Endothelin Antagonists Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 125. GSK Plc Endothelin Antagonists Therapeutics Product Offerings
Table 126. GSK Plc Recent Development
Table 127. Key Raw Materials Lists
Table 128. Raw Materials Key Suppliers Lists
Table 129. Endothelin Antagonists Therapeutics Downstream Customers
Table 130. Endothelin Antagonists Therapeutics Distributors List
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Endothelin Antagonists Therapeutics Product Picture
Figure 2. Global Endothelin Antagonists Therapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Endothelin Antagonists Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Endothelin Antagonists Therapeutics Sales Volume (2019-2030) & (K Units)
Figure 5. Global Endothelin Antagonists Therapeutics Sales Price (2019-2030) & (US$/Unit)
Figure 6. Endothelin Antagonists Therapeutics Report Years Considered
Figure 7. Global Endothelin Antagonists Therapeutics Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Endothelin Antagonists Therapeutics Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Endothelin Antagonists Therapeutics Revenue in 2023
Figure 10. Endothelin Antagonists Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Oral Picture
Figure 12. Parenteral Picture
Figure 13. Global Endothelin Antagonists Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Endothelin Antagonists Therapeutics Sales Value Market Share by Type, 2023 & 2030
Figure 15. Global Endothelin Antagonists Therapeutics Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 16. Global Endothelin Antagonists Therapeutics Sales Volume Market Share by Type, 2023 & 2030
Figure 17. Global Endothelin Antagonists Therapeutics Price by Type (2019-2030) & (US$/Unit)
Figure 18. Product Picture of Cardiovascular Diseases
Figure 19. Product Picture of Scleroderma
Figure 20. Product Picture of Other
Figure 21. Global Endothelin Antagonists Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global Endothelin Antagonists Therapeutics Sales Value Market Share by Application, 2023 & 2030
Figure 23. Global Endothelin Antagonists Therapeutics Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 24. Global Endothelin Antagonists Therapeutics Sales Volume Market Share by Application, 2023 & 2030
Figure 25. Global Endothelin Antagonists Therapeutics Price by Application (2019-2030) & (US$/Unit)
Figure 26. North America Endothelin Antagonists Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 27. North America Endothelin Antagonists Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 28. Europe Endothelin Antagonists Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 29. Europe Endothelin Antagonists Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 30. Asia Pacific Endothelin Antagonists Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Endothelin Antagonists Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 32. South America Endothelin Antagonists Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 33. South America Endothelin Antagonists Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 34. Middle East & Africa Endothelin Antagonists Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 35. Middle East & Africa Endothelin Antagonists Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 36. Key Countries/Regions Endothelin Antagonists Therapeutics Sales Value (%), (2019-2030)
Figure 37. Key Countries/Regions Endothelin Antagonists Therapeutics Sales Volume (%), (2019-2030)
Figure 38. United States Endothelin Antagonists Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 39. United States Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 40. United States Endothelin Antagonists Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 41. Europe Endothelin Antagonists Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 42. Europe Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 43. Europe Endothelin Antagonists Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 44. China Endothelin Antagonists Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 45. China Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 46. China Endothelin Antagonists Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 47. Japan Endothelin Antagonists Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 48. Japan Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 49. Japan Endothelin Antagonists Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 50. South Korea Endothelin Antagonists Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 51. South Korea Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 52. South Korea Endothelin Antagonists Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 53. Southeast Asia Endothelin Antagonists Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 54. Southeast Asia Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 55. Southeast Asia Endothelin Antagonists Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 56. India Endothelin Antagonists Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 57. India Endothelin Antagonists Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 58. India Endothelin Antagonists Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 59. Endothelin Antagonists Therapeutics Industrial Chain
Figure 60. Endothelin Antagonists Therapeutics Manufacturing Cost Structure
Figure 61. Channels of Distribution (Direct Sales, and Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Digital Multifunction Meter - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Oct 12, 24
Whole Current Energy Meter - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Oct 12, 24
High Current Air Circuit Breaker - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Oct 12, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232